WebNov 17, 2024 · Syncona Ltd, (“Syncona” or the “Company”), a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science, today announces its Interim Results for the six months ended 30 September 2024. Positive operational and clinical progress across the portfolio against a challenging macro ... WebNov 19, 2024 · The Syncona team will work closely with Purespring as it builds out its operations and management team. Dominic Schmidt, Partner, Syncona Investment Management Limited, said: "We believe that the foundation of Purespring represents a unique opportunity to build the global leader in renal gene therapy, where we will have a …
Update re. Silicon Valley Bank – Company Announcement - FT.com
WebMar 24, 2024 · Syncona Corporate presentation March 2024 synconaltd.com Image Freeline labs, Stevenage ... April 2, 2024. Advanced search ... Strong track record and expert team with deep scientific and commercial expertise and extensive experience working with global key opinion leaders and appointing leading management teams. WebOct 1, 2024 · Syncona, is a leading FTSE 250 healthcare company focused on creating, building and scaling a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio ... face wash products for oily skin
Clade Therapeutics Next-generation stem cell-based medicines
WebThe Syncona team has deep scientific, investment, operational and commercial expertise. Balance sheet provides the flexibility to take a long-term approach to building and funding companies. Setting companies up with the capability to take products to approval can deliver the best risk-adjusted returns. WebSyncona's CEO is Martin Murphy. Other executives include Virginia Holmes, Senior Independent Director; Chris Hollowood, Chief Investment Officer and 18 others. See the full leadership team at Craft. WebJun 13, 2024 · The Syncona team is working in close partnership with the company to build the business, focusing on developing the clinical plan and strategy. We also announced the foundation of a new company, Quell Therapeutics, bringing together six leading academics in the cell therapy space with a GBP35 million Series A financing. face wash scrub brush